PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Oncogene. Author manuscript; available in PMC 2013 July 15.
Published in final edited form as:
PMCID: PMC3711644
NIHMSID: NIHMS321956

EGFR-dependent pancreatic carcinoma cell metastasis via Rap1 activation

Abstract

Tyrosine kinase receptors play an essential role in various aspects of tumor progression. In particular, epidermal growth factor receptor (EGFR) and its ligands have been implicated in the growth and dissemination of a wide array of human carcinomas. Here, we describe an EGFR-mediated signaling pathway that regulates human pancreatic carcinoma cell invasion and metastasis, yet does not influence the growth of primary tumors. In fact, ligation/activation of EGFR induces Src-dependent phosphorylation of two critical tyrosine residues of p130CAS, leading to assembly of a CAS/Nck1 complex that promotes Rap1 signaling. Importantly, GTP loading of Rap1 is specifically required for pancreatic carcinoma cell migration on vitronectin, but not on collagen. Furthermore, Rap1 activation is required for EGFR-mediated metastasis in vivo without impacting primary tumor growth. These findings identify a molecular pathway that promotes the invasive/metastatic properties of human pancreatic carcinomas driven by EGFR.

Keywords: pancreatic cancer, Rap1, CAS, EGFR, metastasis, tyrosine phosphorylation

INTRODUCTION

While the significance of metastatic burden on mortality from pancreatic carcinoma is well appreciated, the molecular mechanisms that govern such aggressive invasive behavior remain poorly understood. Current efforts have focused on targeted therapies including inhibitors of EGFR signaling, a pathway which is often dysregulated in pancreatic adenocarcinoma (Rivera et al., 2009). However, resistance to anti-EGFR therapies frequently occurs through mechanisms that activate downstream mediators independent of EGFR-activation (Faller and Burtness, 2009). This could include signaling through other growth factor receptors, such as recepteur d’Origine nantais (RON) and insulin-like growth factor 1 receptor (IGF-1R) (Guix et al., 2008). Both receptors have been shown to cross-talk with EGFR (Morgillo et al., 2006; Peace et al., 2003) and their expression correlates with disease progression (Thomas et al., 2007; Wolpin et al., 2007).

The small GTPase Ras-associated protein 1 (Rap1) is activated downstream of EGFR and is a regulator of integrin activation, cell adhesion and migration (Bos, 2005; Jenei et al., 2005; Shattil et al., 2010; Shimonaka et al., 2003). Rap1 acts as a signaling switch that cycles between an inactive GDP-bound form and an active GTP-bound form with the assistance of guanine exchange factors (GEFs) and GTPase activating proteins (GAPs). Because of its low intrinsic GTPase activity, Rap1 relies on GTP hydrolysis by GAPs such as Rap1GAP, which has been identified as a putative tumor suppressor deficient in pancreatic carcinoma. Ectopic expression of Rap1GAP inhibits migration in pancreatic carcinoma cells and serves as a metastasis suppressor, which suggests that Rap1 activity is a critical determinant of tumor cell invasiveness (Zhang et al., 2006).

Previously, we described two distinct pathways of tumor cell migration: one requires a cross-talk between growth factor receptors and the integrin αvβ5, while the other is independent of growth factor receptors and utilizes one or more β1 integrins (Brooks et al., 1997; Klemke et al., 1994). We have also reported that growth factor stimulation of carcinoma cell migration on the αvβ5 substrate vitronectin correlates with the cell’s metastatic properties (Klemke et al., 1998). In fact, EGFR-induced activation of Src family kinases (SFK) is necessary and sufficient for induction of migration on vitronectin in vitro and metastasis in vivo. Subsequent to SFK activation, the adaptor protein Crk-associated substrate (CAS) is phosphorylated on specific tyrosine residues in its substrate domain, which contains 15 YxxP motifs (Ricono et al., 2009).

Deletion of the CAS substrate domain or mutation of all 15 YxxP motifs to FxxP has been shown to block tumor cell migration, invasion and metastasis (Brabek et al., 2005; Klemke et al., 1998). Tyrosine phosphorylation of CAS on the 15 YxxP motifs in its substrate domain creates dockings sites for proteins that contain SH2 domains, including other pro-migratory signaling molecules such as Crk and Nck (Klemke et al., 1998; Rivera et al., 2006; Schlaepfer et al., 1997). In this study, we characterize a novel mechanism of Rap1 activation downstream of EGFR that requires the formation of a CAS/Nck1 complex. Activation of Rap1 is required to promote migration on vitronectin, but not on collagen. Furthermore, Rap1-GTP loading is critical for EGFR-induced metastasis, without enhancing primary tumor growth. Our results reveal new insights in the mechanism of EGFR-mediated metastasis and establish a previously unrecognized connection between the CAS/Nck1 signaling module and Rap1 activation.

RESULTS

Rap1 activation is required for EGFR-mediated metastasis

Hyperactivation of EGFR induces metastasis of a wide range of carcinoma cells (Kim and Muller, 1999; Matsumoto et al., 2006; Papouchado et al., 2005; Ueno et al., 2008). EGF stimulation also results in the selective induction of migration of these cells on a vitronectin substrate in vitro suggesting that EGFR-induced migration on vitronectin might recapitulate specific aspects of metastatic invasion in the context of EGFR stimulation in vivo (Brooks et al., 1997; Klemke et al., 1994; Ricono et al., 2009). Previously, we implicated a role for Rap1 specifically in EGFR-dependent migration on vitronectin in human FG pancreatic tumor cells (Ricono et al., 2009). To determine whether Rap1 is also required for EGFR-mediated metastasis, FG cells stably expressing either non-silencing shRNA or Rap1 shRNA were treated with or without EGF ex vivo and subsequently implanted on the chorioallantoic membrane (CAM) of 10-day-old chick embryos. Primary tumor growth and spontaneous pulmonary metastasis were quantified as described (Ricono et al., 2009). Consistent with our previous finding that Rap1 is required for EGFR-mediated migration on vitronectin of FG cells (Ricono et al., 2009) and with BxPC3 pancreatic tumor cells (data not shown), silencing Rap1 expression blocks EGFR-induced metastasis without affecting primary tumor growth (Fig. 1A). Furthermore, we assessed the role for Rap1 activation in EGFR-mediated metastasis. To address this, we expressed Rap1GAP in FG cells to block EGFR-dependent Rap1 activation (Fig. 1B, bottom). Inhibition of Rap1 activity suppresses the EGFR-induced metastatic response without influencing the primary tumor size (Fig. 1B). Thus, Rap1 activation is required for EGFR-mediated metastasis. These findings are consistent with previous results implicating Rap1 activation in tumor cell invasion and metastasis (Bailey et al., 2009; Furstenau et al., 2010; Mitra et al., 2008). To determine whether Rap1 activation is sufficient to induce metastasis in the absence of EGFR stimulation, FG cells stably expressing either empty vector, WT, constitutively active Rap1 (Rap1 G12V) or an inactive Rap1 (Rap1 S17N) were implanted on the chick CAM. Compared to cells expressing either empty vector or inactive Rap1, cells expressing active Rap1 showed a significant increase in spontaneous pulmonary metastasis yet did not show an increase in primary tumor growth in vivo (Fig. 1C). These findings support the notion that Rap1 plays a critical role in the metastatic properties of these cells and is an important mediator of metastasis downstream of EGFR.

Figure 1
Rap1 activation is required for EGFR-mediated metastasis

We next considered whether Rap1 activation, which induces spontaneous carcinoma metastasis in vivo, might initiate carcinoma cell migration on a vitronectin substrate in vitro. FG cells stably expressing empty vector, active, inactive or WT Rap1 were allowed to migrate on either a vitronectin or collagen matrix. We found that active Rap1 was sufficient for migration on vitronectin, but to our surprise did not influence FG cell migration on collagen (Fig. 1D). These findings closely mirrored the effects of EGF stimulation as previously reported (Klemke et al., 1994).

In addition to EGF, other growth factors are known to induce Rap1 activity. Therefore we examined FG cell migration and Rap1 activation following a brief exposure (10–30 minutes) to various growth factors implicated in pancreatic cancer including EGF, insulin-like growth factor (IGF) or macrophage stimulating protein (MSP). While each growth factor induced Rap1 activity and induced FG cell migration on vitronectin, none stimulated their migratory response on collagen (Fig. 1 E, F). Therefore, distinct growth factors induce Rap1-GTP loading and tumor cell migration on a vitronectin substrate.

Next, we sought to identify which RapGEF(s) promotes migration and Rap1-GTP loading in response to EGF stimulation. Of the six known Rap specific GEFs, FG cells express RapGEF2 and RapGEF6 (data not shown). Knockdown of both RapGEFs blocks EGFR-induced migration on vitronectin (Fig. S1A) and EGFR-dependent Rap1-GTP loading (Fig. S1B). Altogether, these results might explain in part how EGF and other growth factors promote the invasive properties of carcinoma cells in vitro and in vivo.

Src and CAS are required for EGFR-dependent migration and Rap1 activation

EGF stimulation promotes the activation of Src kinase, a known contributor to tumor cell invasion (Summy and Gallick, 2003; Trevino et al., 2006). Previously, we showed that Src activation is required for EGFR-mediated spontaneous metastasis of carcinoma cells (Ricono et al., 2009). In fact, stimulation of FG cells with EGF, IGF or MSP leads to the phosphorylation of the Y416 activation site on Src (Fig. 2A). Transient knockdown of Src in FG cells disrupted EGFR-mediated Rap1-GTP loading (Fig. 2B) and blocked migration on vitronectin (Fig. 2C), but not on collagen (data not shown) suggesting Rap1 activation by EGFR was Src dependent.

Figure 2
Src and CAS are required for EGFR-dependent migration and Rap1 activation

The adaptor protein p130CAS (CAS), a prominent Src substrate, plays a key role in cell migration and invasion (Huang et al., 2002; Klemke et al., 1998; Shin et al., 2004). Indeed, EGF induces phosphorylation of CAS in a Src-dependent manner since knockdown of Src prevented EGFR-dependent phosphorylation of CAS (Fig. 2D). Furthermore, down-regulation of CAS also blocked EGFR-induced Rap1-GTP loading (Fig. 2E). Lastly, knockdown of CAS abolished EGFR-mediated carcinoma cell migration on vitronectin (Fig. 2F) while it had no effect on cell migration on collagen (data now shown). These results indicate that Src and CAS are both required for growth factor mediated Rap1 activation and the resulting cell migration response on a vitronectin substrate.

Nck1, a CAS binding partner, is necessary for EGFR-mediated migration, metastasis and Rap1-GTP loading

The role of CAS in cell migration is linked to its capacity to recruit a range of signaling molecules including the adaptor proteins Crk and Nck (Klemke et al., 1998; Rivera et al., 2006). To assess whether Crk and Nck were associated with the induction of EGFR-mediated carcinoma cell migration, lysates from FG cells treated with or without EGF were subjected to immunoprecipitation with anti-CAS followed by immunoblotting for Nck1, Nck2, CrkL and CrkI. EGF stimulation increased the association of both Nck1 and Nck2 with CAS but not CrkL or CrkI with CAS (Fig. 3A). We next evaluated the significance of these proteins in EGFR-dependent migration on vitronectin. Interestingly, knockdown of Nck1 but not Nck2 selectively suppressed EGFR-induced cell migration on vitronectin (Fig. 3B). However, knockdown of either CrkL or CrkI inhibited cell migration in general, blocking both EGFR-mediated cell migration on vitronectin as well as the constitutive cell migration on collagen (Fig. S2). In support of these observations, knockdown of Nck1 also disrupted EGFR-mediated Rap1-GTP loading (Fig. 3C). These findings indicate that Nck1 is specifically required for the EGFR-mediated carcinoma cell migration response while both Crk family members appear to have a more generalized role in carcinoma cell migration. These results also suggest that EGF can lead to Src-mediated phosphorylation of CAS, recruitment of Nck1 and induction of Rap1 activation. Thus, Nck1 through its coupling to CAS appears to be required for the EGFR-mediated cell migration on vitronectin. Therefore we considered whether Nck1 was also required for the spontaneous metastasis of carcinoma cells in vivo. FG cells subjected to Nck1 knockdown and ex vivo stimulation of EGF were compared to control cells and analyzed for their primary tumor growth and spontaneous metastasis in the chick CAM model. Consistent with our in vitro observations, Nck1 shRNA was sufficient to block the EGFR-induced metastasis, while having no effect on the primary tumor size (Fig. 3D). Altogether our data implicate Nck1 and its association with CAS as a key signaling module that regulates EGFR-mediated Rap1 activation, tumor cell invasion and metastasis.

Figure 3
Nck1, a CAS binding partner, is necessary for EGFR-mediated migration, metastasis and Rap1-GTP loading

EGFR-induced metastasis, CAS/Nck1 association and Rap1-GTP loading require CAS Y253/Y271

To characterize the mechanism by which Nck1 associates with CAS and thereby influences tumor cell metastasis we considered the fact that CAS contains a substrate domain characterized by 15 YxxP motifs which serve as putative docking sites for SH2 domain containing proteins including Nck1 (Shin et al., 2004). A number of these sites have been linked to cell migration and metastasis and are known to represent substrates for Src (Brabek et al., 2004; Brabek et al., 2005; Goldberg et al., 2003). Therefore, we performed a mutational analysis of CAS to identify possible Src tyrosine phosphorylation sites on CAS that might serve to recruit Nck1 which initiates pro-metastatic signals. In a previous study we reported that one or more of the first nine tyrosines among the fifteen found within the CAS substrate domain were required for EGFR-dependent metastasis (Ricono et al., 2009). Therefore, we considered whether one or more tyrosines within the first nine YxxP motifs in the CAS substrate domain might play a role in EGFR-mediated carcinoma cell invasion and metastasis. We stably expressed a range of Y-F point mutations within the substrate domain of CAS and found that CAS Y253F (referred to as “F7”) or Y271F (referred to as “F8”) or the CAS Y253F/Y271F double mutant (referred to as “F7/F8”) was sufficient to block EGFR-mediated migration on vitronectin (Fig. 4A, B) without affecting cell migration on collagen (data not shown). As previously reported (Ricono et al., 2009) the CAS F1–15 mutant (mutation of all 15 YxxP motifs in the substrate domain) blocks EGFR-induced migration; however, restoration of Y253 and Y271 (referred to as “Y7/Y8”) within the CAS F1–15 construct was sufficient to enhance EGFR-dependent migration similarly to WT CAS (Fig. 4B). Furthermore, the F7/F8 CAS mutant inhibits EGFR-induced Rap1 activation, while the Y7/Y8 CAS mutant allows for EGFR-mediated Rap1-GTP loading (Fig. 4C).

Figure 4
EGFR-induced metastasis, CAS/Nck1 association and Rap1-GTP loading require CAS Y253/Y271

Y253 and Y271 are putative Src phosphorylation sites (Goldberg et al., 2003; Shin et al., 2004) that are phosphorylated in response to EGF stimulation (Fig. S3A). To confirm a role for Src in the phosphorylation of these tyrosine residues, we transiently transfected WT CAS, F1–15, F7/F8 (Y253F/Y271F) or Y7/Y8 CAS in FG cells stably expressing an empty vector or a constitutively active Src construct (Src Y527F or “SrcA”). CAS was immunoprecipitated from these cells and immunoblotted for CAS phosphorylation. The F7/F8 mutant exhibited a significant decrease in CAS phosphorylation compared to WT CAS, while the Y7/Y8 mutant rescued Src-dependent phosphorylation (Fig. S3B). To evaluate the importance of phosphorylation of these sites on migration, we compared the SrcA cells co-transfected with the each of the CAS mutants. SrcA cells expressing WT CAS showed an increased migration response on vitronectin compared to SrcA alone. However, SrcA cells expressing the CAS F7/F8 mutant, like those expressing CAS F1–15, failed to show the increased cell migration on vitronectin. Importantly, expression of the Y7/Y8 within the context of CAS F1–15 reversed the phenotype suggesting these sites are sufficient to account for the role that Src and CAS play in carcinoma cell migration on vitronectin (Fig. S3C).

Because CAS tyrosines 7 and 8 appear to have a significant role in EGFR-induced migration as well as Rap1 activation, we considered whether they serve as docking sites for Nck1. To investigate this, we stably expressed FG cells with a HA-tagged Nck1 construct containing point mutations at each of the three SH3 domains (W38K, W143K, W229K) to ensure CAS binds to the SH2 domain instead of the SH3 domains of Nck1. These cells were then transfected with FLAG-tagged WT CAS, F7/F8 CAS, F1–15 CAS or Y7/Y8 CAS constructs. EGF stimulation of WT CAS or Y7/Y8 CAS expressing cells resulted in a specific increase in HA-Nck1/FLAG-CAS complex, while no increase was seen in the F7/F8 or the F1–15 CAS expressing cells (Fig. 4D). These findings indicate that Y7 and Y8 serve as docking sites for Nck1 on CAS enabling the assembly of a scaffold required for Rap1 activation leading to tumor cell invasion and metastasis. To substantiate this possibility, we treated the WT CAS and F7/F8 CAS with or without EGF, implanted them on the chick CAM and monitored their primary tumor growth and spontaneous pulmonary metastasis. As expected, EGF stimulation promoted a significant increase in lung metastasis of cells expressing WT CAS, whereas EGF stimulation of cells expressing F7/F8 CAS had no effect on tumor growth or metastasis (Fig. 4E). These results demonstrate that Y253 and Y271 sites in CAS are able to recruit Nck1 and thereby play a significant role in EGFR-dependent CAS/Nck1 association, Rap1 activation, migration and metastasis (Fig. 5).

Figure 5
EGFR activates migration and metastasis via a CAS/Nck1/Rap1 signaling module

DISCUSSION

While mutations in EGFR are rare in pancreatic ductal adenocarcinoma, overexpression of EGFR occurs in over half of all pancreatic cancers and correlates with poor prognosis (Morgan et al., 2008) and metastasis (Pryczynicz et al., 2008). In animal models of pancreatic cancer, gemcitabine treatment in combination with anti-EGFR therapy significantly inhibited metastasis to the liver and lymph node (Bruns et al., 2000). EGF-induced activation of EGFR stimulates cells to rapidly acquire an invasive or metastatic phenotype (Lotz et al., 2003; Lu et al., 2003). In fact, we recently found that carcinoma cells transiently exposed to EGF gain the capacity to invade and metastasize in vivo (Ricono et al., 2009).

In this study we characterized the effectors involved in EGFR-mediated cell invasion and metastasis of human pancreatic carcinoma cells. We examined the role of the GTPase Rap1 in this process since Rap1 is activated downstream of EGF stimulation (Mochizuki et al., 2001; Ohba et al., 2003) and has been associated with the induction of integrin activation (Retta et al., 2006). Rap1 has also previously been associated with the invasive properties of a wide range of tumor cells including: melanoma (Gao et al., 2006), prostate cancer (Bailey et al., 2009), thyroid cancer (Tsygankova et al., 2007), colon cancer (Tsygankova et al., 2010) and pancreatic cancer (Zhang et al., 2006). Indeed, we found that EGFR-mediated metastasis requires the EGFR-dependent activation of Rap1 (Fig. 1B). Interestingly, EGF, IGF or MSP stimulation of FG cells results in increased cell migration on vitronectin as well as Rap1-GTP loading (Fig. 1E, F). Thus, Rap1 appears to be an important regulator of tumor cell metastasis downstream of multiple growth factor receptors.

Knowing that EGFR could promote Rap1 activation leading to increased metastasis of carcinoma cells, we sought to characterize the effectors leading to the activation of Rap1 to gain a better understanding of how EGFR leads to tumor invasion and metastasis. In previous studies, we determined that EGFR-mediated Src activation leads to the tyrosine phosphorylation of CAS, a focal contact localized scaffolding protein previously linked to cell migration and invasion (Brabek et al., 2004; Huang et al., 2002; Klemke et al., 1998). CAS phosphorylation is known to recruit a wide range of adaptor molecules and kinases linked to cell invasive behavior where it appears to play a critical role in the migratory property of various cells (Klemke et al., 1998; Shin et al., 2004). However, we observed that genetic knockdown of CAS inhibited EGFR-induced carcinoma cell migration, yet to our surprise did not disrupt migration on collagen (Fig. 2F). Furthermore, CAS knockdown also blocked EGFR-mediated Rap1-GTP loading. These findings suggest that CAS, once phosphorylated in pancreatic cancer cells, promotes the assembly of a signaling complex that leads to activation of Rap1 and metastasis. Indeed, this pathway was found to depend on the Src phosphorylation of 2 of 15 tyrosine sites (Y253 and Y271) within the CAS substrate domain. While Src phosphorylates CAS on multiple tyrosine residues (Goldberg et al., 2003; Shin et al., 2004), CAS Y253 and Y271 together are critical for EGFR-dependent migration, metastasis and Rap1 activation.

CAS has a prominent role in migration due to its binding with the adaptor protein Crk as well as a number of other effectors. Specifically, studies have identified the assembly of a CAS/Crk/Dock180/Rac1 signaling axis as playing a key role in the cell migration response (Cheresh et al., 1999; Gu et al., 2001; Payne et al., 2006). In fact, the CAS/Crk complex has been described as a “molecular switch” in a general role for cell migration (Klemke et al., 1998). However, our current study demonstrates that EGF stimulation of FG pancreatic carcinoma cells does not increase the association of CAS with either CrkL or CrkI, consistent with their generalized role in migration on either collagen or vitronectin substrates. In contrast, Nck1, but not Nck2, is specifically involved in EGFR-dependent migration and metastasis since EGF stimulation of FG cells specifically enhances Nck1 association with CAS, which utilizes CAS Y253 and Y271 as docking sites for the Nck1 SH2 domain.

CAS phosphorylation has been linked to Rap1 activation through the assembly of a CAS/Crk complex with Crk binding to the RapGEF C3G (Sakakibara et al., 2002; Tamada et al., 2004). Our results, however, indicate a novel requirement for Nck1 in EGFR-mediated Rap1 activation in a CAS dependent manner. In fact, Nck1 could promote Rap1-GTP loading by recruiting RapGEFs with Rap1. Although knockdown of RapGEF2 and RapGEF6 inhibits EGFR-mediated migration on vitronectin and Rap1 activation, we cannot rule out other GEFs that may also influence this pathway of Rap1-GTP loading (Frische and Zwartkruis, 2010; Xu et al., 2007; Yaman et al., 2009).

Here, we have identified an EGFR/Src/CAS/Nck1/Rap1 signaling axis that promotes migration on vitronectin and spontaneous metastasis of human pancreatic carcinoma cells (Fig. 5). We used a chick chorioallantoic membrane model which enabled us to quantify both primary tumor growth and spontaneous metastasis following a brief treatment of cells to EGF ex vivo. Our results underscore the importance for Rap1-GTP in tumor cell invasion and metastasis. Importantly, Rap1-GTP loading may also be a convergence point for multiple growth factor regulated metastatic signaling pathways, as EGF, IGF, and MSP stimulation all promote migration on vitronectin and Rap1-GTP loading. These findings suggest that antagonists of Rap1 might be particularly useful therapeutic agents to suppress the progression of various epithelial derived cancers that are typically exposed to a wide range of cytokines.

MATERIALS AND METHODS

Cell culture

Mycoplasma-negative 293T, FG and BxPC3 human pancreatic carcinoma cells (Klemke et al., 1998) were grown in DMEM (Life Technologies, Carlsbad, CA) with 10% fetal bovine serum. FG cells containing CAS or Nck1 mutations were FACS sorted for green fluorescent protein expression, and CAS or Nck1 expression was verified by immunoblotting. FG cells containing Rap1 mutations were FACS sorted for red fluorescent protein expression, and Rap1 expression was verified by immunoblotting.

Growth factors and Antibodies

Growth factor stimulation was performed with EGF (Millipore, Temecula, CA), IGF-1 (Sigma-Aldrich, St. Louis, MO) or MSP (R&D Systems, Minneapolis, MN). Antibodies were purchased for CAS, Erk2, RapGEF6, HSP90, CrkL (Santa Cruz Biotechnology, Santa Cruz, CA), HSP60 (Enzo Life Sciences, Plymouth Meeting, PA), CrkI, Nck1 (B.D. Biosciences, San Jose, CA), 4G10, Rap1, Nck2 (Millipore, Temecula, CA), HA (Abcam, Cambridge, MA), FLAG M2 (Sigma-Aldrich, St. Louis, MO), pSrc Y416, pCAS Y249 (Cell Signaling Technology, Danvers, MA), RapGEF2 (Abnova, Taiwan). Sepharose conjugated antibodies were also purchased for Anti-FLAG-M2 and anti-HA (Sigma-Aldrich, St. Louis, MO).

Plasmids

Rap1GAP and Nck1 cDNA was tagged with 3xHA and subcloned into the pCDH vector backbone (CD511-B1 from System Biosciences). Mutant CAS cDNA was amplified from pRc/CMV-CAS templates (Shin et al., 2004), tagged with 3xFLAG and subcloned into the pCDH vector backbone. Rap1 cDNA was also tagged with 3xFLAG and subcloned into the pCDH vector backbone.

siRNA and shRNA knockdown

Rap1, Nck1 and nonsilencing lentiviral shRNAmir in GIPZ expression system were purchased from Open Biosystems, Huntsville, AL. Lentiviruses were produced in 293T cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Cells were selected 48 h after infection with 1 µg/mL puromycin, and low-expressing cells were further selected by flow cytometry.

Transient knockdowns were performed with siRNA against Src, CAS, CrkL, CrkI, Nck1, Nck2, RapGEF2, RapGEF6 (Qiagen, Valencia CA). Transfection of siRNA was carried out using Amaxa Nucleofector Kit V for FG cells and Nucleofector Kit L for BxPC3 cells (Lonza, CH-4002 Basel, Switzerland), according to the manufacturer's guidelines.

Immunoblotting and Immunoprecipitation

For analysis of protein complexes, cells were lysed in SDS lysis buffer (50mM Tris pH 7.4, 150mM NaCl, 0.1% SDS, 2mM EDTA, Protease inhibitor cocktail (Roche), 2mM NaF, 1 mM sodium vanadate) and pulled down with the indicated conjugated antibody or antibody with protein A/G beads (Pierce Protein Research) overnight in 4° C. Beads were washed three times in PBS, resuspended in Laemmli buffer and analyzed on 10% SDS-PAGE. For whole cell lysates, cells were lysed in modified RIPA buffer (50mM Tris pH 7.4, 150mM NaCl, 0.1% SDS, 1% Triton-x, 2mM EDTA, protease inhibitor cocktail (Roche, South San Francisco, CA), 2mM NaF, 1 mM sodium vanadate) and analyzed on 10% SDS-PAGE.

Migration assays

We performed haptotaxis migration assays on 6.5 mm diameter 8 µm pore size Transwell inserts (B.D. Biosciences) as previously described (Klemke et al., 1994).

Chick embryo metastasis

The chick embryo metastasis assay was performed as described (Brooks et al., 1997).

Rap1 activity assays

Rap1-GTP pull-down assays were performed according to the manufacturer's instructions (Millipore).

Statistics

Unless stated otherwise, bar graphs represent mean ± SD of triplicate samples. All data presented are representative of at least two experiments. P values were generated by two-tailed t test.

Supplementary Material

1

Supplementary Figure S1. (a) FG cells were transiently transfected with control siRNA or RapGEF2 siRNA and RapGEF6 siRNA. After 24h, cells were serum starved overnight, subsequently treated with or without EGF and analyzed for migration on vitronectin or collagen. *p < 0.01. (b) FG cells were transiently transfected with control siRNA, RapGEF2 siRNA or RapGEF6 siRNA. After 24h, cells were serum starved overnight, subsequently treated with or without EGF and analyzed for Rap1 activation. Data in a represent the mean±s.e.m. of triplicates and are representative of two independent experiments.

2

Supplementary Figure S2. FG cells were transiently transfected with control siRNA, CrkL siRNA, or CrkI siRNA. After 24h, cells were serum starved overnight, subsequently treated with or without EGF and analyzed for migration on vitronectin or collagen. *p < 0.01. Data represent the mean±s.e.m. of triplicates and are representative of three independent experiments.

3

Supplementary Figure S3. (a) FG cells transiently transfected with FLAG-tagged WT CAS or F7/F8 CAS. After 24h, cells were serum starved overnight, treated with or without EGF for 10 minutes and lysed. Lysates were immunoprecipitated with anti-FLAG and analyzed by immunoblotting for phospho-CAS followed by anti-FLAG (loading control) (b) FG cells stably expressing empty vector or SrcA were also transiently transfected with FLAG-tagged WT CAS, F7/F8 CAS, F1–15 CAS or Y7/Y8 CAS. After 24h, cells were serum starved overnight and lysed. Lysates were immunoprecipitated with anti-FLAG and analyzed by immunoblotting for phospho-CAS followed by anti-FLAG (loading control). (c) FG cells stably expressing SrcA (Src Y527F) were transiently transfected with empty vector, FLAG-tagged WT CAS, F7/F8 CAS, F1–15 CAS or Y7/Y8 CAS and analyzed for their migration phenotype on vitronectin. *p < 0.01. Data in c represent the mean±s.e.m. of triplicates and are representative of two independent experiments.

Acknowledgements

We would like to thank Dr. Steven K. Hanks for the generous donation of the CAS mutant plasmids and Dr. David J. Shields for his helpful discussion. This work was supported by NIH grants CA107263 (D.G.S.), HL56595 and HL47900 (S.J.S), CA102310 (D.D.S.), and CA045726 (D.A.C.).

Footnotes

Conflict of Interest: The authors declare no conflict of interest.

Supplementary information is available at Oncogene’s website

REFERENCES

  • Bailey CL, Kelly P, Casey PJ. Activation of Rap1 promotes prostate cancer metastasis. Cancer Res. 2009;69:4962–4968. [PubMed]
  • Bos JL. Linking Rap to cell adhesion. Current Opinion in Cell Biology. 2005;17:123–128. [PubMed]
  • Brabek J, Constancio SS, Shin NY, Pozzi A, Weaver AM, Hanks SK. CAS promotes invasiveness of Src-transformed cells. Oncogene. 2004;23:7406–7415. [PubMed]
  • Brabek J, Constancio SS, Siesser PF, Shin NY, Pozzi A, Hanks SK. Crk-Associated Substrate Tyrosine Phosphorylation Sites Are Critical for Invasion and Metastasis of Src-Transformed Cells. Mol Cancer Res. 2005;3:307–315. [PubMed]
  • Brooks PC, Klemke RL, Schon S, Lewis JM, Schwartz MA, Cheresh DA. Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo. J Clin Invest. 1997;99:1390–1398. [PMC free article] [PubMed]
  • Bruns CJ, Solorzano CC, Harbison MT, Ozawa S, Tsan R, Fan D, et al. Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 2000;60:2926–2935. [PubMed]
  • Cheresh DA, Leng J, Klemke RL. Regulation of cell contraction and membrane ruffling by distinct signals in migratory cells. J Cell Biol. 1999;146:1107–1116. [PMC free article] [PubMed]
  • Faller BA, Burtness B. Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics. 2009;3:419–428. [PMC free article] [PubMed]
  • Frische EW, Zwartkruis FJ. Rap1, a mercenary among the Ras-like GTPases. Dev Biol. 2010;340:1–9. [PubMed]
  • Furstenau DK, Mitra N, Wan F, Lewis R, Feldman MD, Fraker DL, et al. Ras-related protein 1 and the insulin-like growth factor type I receptor are associated with risk of progression in patients diagnosed with carcinoma in situ. Breast Cancer Res Treat. 2010 [PubMed]
  • Gao L, Feng Y, Bowers R, Becker-Hapak M, Gardner J, Council L, et al. Ras-associated protein-1 regulates extracellular signal-regulated kinase activation and migration in melanoma cells: two processes important to melanoma tumorigenesis and metastasis. Cancer Res. 2006;66:7880–7888. [PubMed]
  • Goldberg GS, Alexander DB, Pellicena P, Zhang ZY, Tsuda H, Miller WT. Src phosphorylates Cas on tyrosine 253 to promote migration of transformed cells. J Biol Chem. 2003;278:46533–46540. [PMC free article] [PubMed]
  • Gu J, Sumida Y, Sanzen N, Sekiguchi K. Laminin-10/11 and fibronectin differentially regulate integrin-dependent Rho and Rac activation via p130(Cas)-CrkII-DOCK180 pathway. J Biol Chem. 2001;276:27090–27097. [PubMed]
  • Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGFbinding proteins. J Clin Invest. 2008;118:2609–2619. [PMC free article] [PubMed]
  • Huang J, Hamasaki H, Nakamoto T, Honda H, Hirai H, Saito M, et al. Differential regulation of cell migration, actin stress fiber organization, and cell transformation by functional domains of Crk-associated substrate. J Biol Chem. 2002;277:27265–27272. [PubMed]
  • Jenei V, Andersson T, Jakus J, Dib K. E3B1, a human homologue of the mouse gene product Abi-1, sensitizes activation of Rap1 in response to epidermal growth factor. Exp cell Res. 2005;310:463–473. [PubMed]
  • Kim H, Muller WJ. The role of the epidermal growth factor receptor family in mammary tumorigenesis and metastasis. Exp cell Res. 1999;253:78–87. [PubMed]
  • Klemke RL, Leng J, Molander R, Brooks PC, Vuori K, Cheresh DA. CAS/Crk coupling serves as a "molecular switch" for induction of cell migration. J Cell Biol. 1998;140:961–972. [PMC free article] [PubMed]
  • Klemke RL, Yebra M, Bayna EM, Cheresh DA. Receptor tyrosine kinase signaling required for integrin alpha v beta 5-directed cell motility but not adhesion on vitronectin. J Cell Biol. 1994;127:859–866. [PMC free article] [PubMed]
  • Lotz M, Wang HH, Cance W, Matthews J, Pories S. Epidermal growth factor stimulation can substitute for c-Src overexpression in promoting breast carcinoma invasion. J Surg Res. 2003;109:123–129. [PubMed]
  • Lu Z, Ghosh S, Wang Z, Hunter T. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of beta-catenin, and enhanced tumor cell invasion. Cancer Cell. 2003;4:499–515. [PubMed]
  • Matsumoto S, Takahashi K, Iwakawa R, Matsuno Y, Nakanishi Y, Kohno T, et al. Frequent EGFR mutations in brain metastases of lung adenocarcinoma. Int J Cancer. 2006;119:1491–1494. [PubMed]
  • Mitra RS, Goto M, Lee JS, Maldonado D, Taylor JM, Pan Q, et al. Rap1GAP promotes invasion via induction of matrix metalloproteinase 9 secretion, which is associated with poor survival in low N-stage squamous cell carcinoma. Cancer Res. 2008;68:3959–3969. [PubMed]
  • Mochizuki N, Yamashita S, Kurokawa K, Ohba Y, Nagai T, Miyawaki A, et al. Spatiotemporal images of growth-factor-induced activation of Ras and Rap1. Nature. 2001;411:1065–1068. [PubMed]
  • Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS. The combination of epidermal growth factor receptor inhibitors with gemcitabine and radiation in pancreatic cancer. Clin Cancer Res. 2008;14:5142–5149. [PMC free article] [PubMed]
  • Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res. 2006;66:10100–10111. [PubMed]
  • Ohba Y, Kurokawa K, Matsuda M. Mechanism of the spatio-temporal regulation of Ras and Rap1. EMBO J. 2003;22:859–869. [PubMed]
  • Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, et al. Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas. Mod Pathol. 2005;18:1329–1335. [PubMed]
  • Payne SL, Hendrix MJ, Kirschmann DA. Lysyl oxidase regulates actin filament formation through the p130(Cas)/Crk/DOCK180 signaling complex. J Cell Biochem. 2006;98:827–837. [PubMed]
  • Peace BE, Hill KJ, Degen SJ, Waltz SE. Cross-talk between the receptor tyrosine kinases Ron and epidermal growth factor receptor. Exp cell Res. 2003;289:317–325. [PubMed]
  • Pryczynicz A, Guzińska-Ustymowicz K, Kemona A, Czyzewska J. Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. Anticancer Res. 2008;28:1399–1404. [PubMed]
  • Retta SF, Balzac F, Avolio M. Rap1: a turnabout for the crosstalk between cadherins and integrins. Eur J Cell Biol. 2006;85:283–293. [PubMed]
  • Ricono JM, Huang M, Barnes LA, Lau SK, Weis SM, Schlaepfer DD, et al. Specific crosstalk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. Cancer Res. 2009;69:1383–1391. [PMC free article] [PubMed]
  • Rivera F, Lopez-Tarruella S, Vega-Villegas ME, Salcedo M. Treatment of advanced pancreatic cancer: from gemcitabine single agent to combinations and targeted therapy. Cancer Treat Rev. 2009;35:335–339. [PubMed]
  • Rivera GM, Antoku S, Gelkop S, Shin NY, Hanks SK, Pawson T, et al. Requirement of Nck adaptors for actin dynamics and cell migration stimulated by platelet-derived growth factor B. Proc Natl Acad Sci U S A. 2006;103:9536–9541. [PubMed]
  • Sakakibara A, Ohba Y, Kurokawa K, Matsuda M, Hattori S. Novel function of Chat in controlling cell adhesion via Cas-Crk-C3G-pathway-mediated Rap1 activation. J Cell Sci. 2002;115:4915–4924. [PubMed]
  • Schlaepfer DD, Broome MA, Hunter T. Fibronectin-stimulated signaling from a focal adhesion kinase-c-Src complex: involvement of the Grb2, p130cas, and Nck adaptor proteins. Mol Cell Biol. 1997;17:1702–1713. [PMC free article] [PubMed]
  • Shattil SJ, Kim C, Ginsberg MH. The final steps of integrin activation: the end game. Mol Cell Biol. 2010;11:288–300. [PubMed]
  • Shimonaka M, Katagiri K, Nakayama T, Fujita N, Tsuruo T, Yoshie O, et al. Rap1 translates chemokine signals to integrin activation, cell polarization, and motility across vascular endothelium under flow. J Cell Biol. 2003;161:417–427. [PMC free article] [PubMed]
  • Shin NY, Dise RS, Schneider-Mergener J, Ritchie MD, Kilkenny DM, Hanks SK. Subsets of the major tyrosine phosphorylation sites in Crk-associated substrate (CAS) are sufficient to promote cell migration. J Biol Chem. 2004;279:38331–38337. [PubMed]
  • Summy JM, Gallick GE. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 2003;22:337–358. [PubMed]
  • Tamada M, Sheetz MP, Sawada Y. Activation of a signaling cascade by cytoskeleton stretch. Dev Cell. 2004;7:709–718. [PubMed]
  • Thomas RM, Toney K, Fenoglio-Preiser C, Revelo-Penafiel MP, Hingorani SR, Tuveson DA, et al. The RON receptor tyrosine kinase mediates oncogenic phenotypes in pancreatic cancer cells and is increasingly expressed during pancreatic cancer progression. Cancer Res. 2007;67:6075–6082. [PubMed]
  • Trevino JG, Summy JM, Lesslie DP, Parikh NU, Hong DS, Lee FY, et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am J Pathol. 2006;168:962–972. [PubMed]
  • Tsygankova OM, Ma C, Tang W, Korch C, Feldman MD, Lv Y, et al. Downregulation of Rap1GAP in human tumor cells alters cell/matrix and cell/cell adhesion. Mol Cell Biol. 2010;30:3262–3274. [PMC free article] [PubMed]
  • Tsygankova OM, Prendergast GV, Puttaswamy K, Wang Y, Feldman MD, Wang H, et al. Downregulation of Rap1GAP contributes to Ras transformation. Mol Cell Biol. 2007;27:6647–6658. [PMC free article] [PubMed]
  • Ueno Y, Sakurai H, Tsunoda S, Choo MK, Matsuo M, Koizumi K, et al. Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer. 2008;123:340–347. [PubMed]
  • Wolpin BM, Michaud DS, Giovannucci EL, Schernhammer ES, Stampfer MJ, Manson JE, et al. Circulating insulin-like growth factor binding protein-1 and the risk of pancreatic cancer. Cancer Res. 2007;67:7923–7928. [PubMed]
  • Xu J, Shi S, Matsumoto N, Noda M, Kitayama H. Identification of Rgl3 as a potential binding partner for Rap-family small G-proteins and profilin II. Cell Signal. 2007;19:1575–1582. [PubMed]
  • Yaman E, Gasper R, Koerner C, Wittinghofer A, Tazebay UH. RasGEF1A and RasGEF1B are guanine nucleotide exchange factors that discriminate between Rap GTP-binding proteins and mediate Rap2-specific nucleotide exchange. FEBS J. 2009;276:4607–4616. [PubMed]
  • Zhang L, Chenwei L, Mahmood R, Van Golen K, Greenson J, Li G, et al. Identification of a putative tumor suppressor gene Rap1GAP in pancreatic cancer. Cancer Res. 2006;66:898–906. [PubMed]